CUMYL-PEGACLONE

CUMYL-PEGACLONE is a synthetic cannabinoid that is also a new psychoactive substance. It was first identified in a smoking mixture in Japan in 2016. It is a derivative of CUMYL-4CN-BINACA but differs in that the 1-amino-3-methyl-1-oxobutanyl group is replaced with a PEG-based structure.

Chemistry

CUMYL-PEGACLONE is a synthetic cannabinoid that is structurally related to the class of drugs as synthetic cannabinoids as AB-CHMINACA. However, the traditional nitrogen moiety is replaced with a structure known as a PEGylated moiety. This change makes it structurally different from other synthetic cannabinoids and it is the first instance where a PEGylated moiety has been used in the design of a new synthetic cannabinoid.

Pharmacology

The pharmacology of CUMYL-PEGACLONE is largely unknown as there have been no formal studies on its effects. However, it is known to be a potent agonist of the CB1 receptor, which is the same receptor that THC, the main active ingredient in cannabis, binds to.

Legal Status

CUMYL-PEGACLONE is currently a legal grey area in many countries. It is not explicitly listed in most national drug laws, but its structural similarity to other illegal cannabinoids could potentially make it illegal under analogue laws in some jurisdictions.

See Also

• Synthetic cannabinoids
• CUMYL-4CN-BINACA
• AB-CHMINACA
• Cannabis

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia